24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion

NCT02361242 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: PXT00864

Sponsor

Pharnext S.C.A.

Collaborators

[object Object]